Expression of SLC17A9 in hepatocellular carcinoma and its clinical significance
The present study aimed to investigate the expression and clinical significance of solute carrier family 17 member 9 (SLC17A9) in cancer tissues of patients with hepatocellular carcinoma (HCC). Ninety-eight patients with HCC were admitted to our hospital from January 2010 to December 2014. Their cli...
Gespeichert in:
| Veröffentlicht in: | Oncology letters 2020-11, Vol.20 (5), p.1-1 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1 |
|---|---|
| container_issue | 5 |
| container_start_page | 1 |
| container_title | Oncology letters |
| container_volume | 20 |
| creator | Wu, Jingdong Yang, Yongfei Song, Jiansheng |
| description | The present study aimed to investigate the expression and clinical significance of solute carrier family 17 member 9 (SLC17A9) in cancer tissues of patients with hepatocellular carcinoma (HCC). Ninety-eight patients with HCC were admitted to our hospital from January 2010 to December 2014. Their clinical data was retrospectively analyzed. The expression of SLC17A9 in HCC cancer tissues was detected by immunohistochemistry. Kaplan-Meier curve, log-rank test and Cox proportional hazard model analysis were used to analyze the tumor-free survival rate and overall survival rate. SLC17A9 expression was associated with Edmondson grade (P=0.04) and distant metastasis (P=0.03). The tumor-free survival (P=0.03) and overall survival (P=0.01) of SLC17A9-high expression patients were significantly lower than those in SLC17A9-low expression patients. Multivariate analysis revealed that SLC17A9 expression (HR, 0.77; 95% CI, 0.27-2.47, P=0.02) was an independent risk factor for tumor-free survival in patients with HCC, and the expression of SLC17A9 (HR, 1.81; 95% CI, 0.99-3.77, P=0.04) was an independent risk factor for overall survival in patients with HCC. In conclusion, SLC17A9 can be used as a new molecular marker to predict the poor prognosis of patients with HCC. Key words: hepatocellular carcinoma, prognosis, molecular marker, SLC17A9, immunohistochemistry |
| doi_str_mv | 10.3892/ol.2020.12043 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7471742</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A638862769</galeid><sourcerecordid>A638862769</sourcerecordid><originalsourceid>FETCH-LOGICAL-c490t-7163234461fb3adb11e621a837c9f14a9329fea23805da523758ab61ca7d77a13</originalsourceid><addsrcrecordid>eNptkk2LFDEQhoMo7jLu0XtAEC895qs7nYswDOsqDOxBPYeadDKTJZ2MSbfovze9u6yOmByqSJ56K1UphF5Tsua9Yu9TWDPCyJoyIvgzdEmlYg0lPXv-5Etxga5KuSN1tR3t--4luuBMcSGFukS31z9P2ZbiU8TJ4S-7LZUbhX3ER3uCKRkbwhwgYwPZ-JhGwBAH7KeCTfDRGwi4-EP0rrrR2FfohYNQ7NWjXaFvH6-_bj81u9ubz9vNrjFCkamRtOOMC9FRt-cw7Cm1HaPQc2mUowJUfaGzwHhP2gFaxmXbw76jBuQgJVC-Qh8edE_zfrSDsXHKEPQp-xHyL53A6_Ob6I_6kH5oKSSVglWBd48COX2fbZn06MtSLUSb5qKZELyt7apmhd78g96lOcda3kLJnrBWyD_UAYLVPrpU85pFVG86XvvOZKcqtf4PVfdgR29StM7X87OAt38FHC2E6VhSmKf6Y-UcbB5Ak1Mp2bqnZlCil2nRKehlWvT9tPDfXlqtLA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2447802547</pqid></control><display><type>article</type><title>Expression of SLC17A9 in hepatocellular carcinoma and its clinical significance</title><source>Spandidos Publications Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Wu, Jingdong ; Yang, Yongfei ; Song, Jiansheng</creator><creatorcontrib>Wu, Jingdong ; Yang, Yongfei ; Song, Jiansheng</creatorcontrib><description>The present study aimed to investigate the expression and clinical significance of solute carrier family 17 member 9 (SLC17A9) in cancer tissues of patients with hepatocellular carcinoma (HCC). Ninety-eight patients with HCC were admitted to our hospital from January 2010 to December 2014. Their clinical data was retrospectively analyzed. The expression of SLC17A9 in HCC cancer tissues was detected by immunohistochemistry. Kaplan-Meier curve, log-rank test and Cox proportional hazard model analysis were used to analyze the tumor-free survival rate and overall survival rate. SLC17A9 expression was associated with Edmondson grade (P=0.04) and distant metastasis (P=0.03). The tumor-free survival (P=0.03) and overall survival (P=0.01) of SLC17A9-high expression patients were significantly lower than those in SLC17A9-low expression patients. Multivariate analysis revealed that SLC17A9 expression (HR, 0.77; 95% CI, 0.27-2.47, P=0.02) was an independent risk factor for tumor-free survival in patients with HCC, and the expression of SLC17A9 (HR, 1.81; 95% CI, 0.99-3.77, P=0.04) was an independent risk factor for overall survival in patients with HCC. In conclusion, SLC17A9 can be used as a new molecular marker to predict the poor prognosis of patients with HCC. Key words: hepatocellular carcinoma, prognosis, molecular marker, SLC17A9, immunohistochemistry</description><identifier>ISSN: 1792-1074</identifier><identifier>EISSN: 1792-1082</identifier><identifier>DOI: 10.3892/ol.2020.12043</identifier><identifier>PMID: 32934749</identifier><language>eng</language><publisher>Athens: Spandidos Publications</publisher><subject>Adenosine triphosphate ; Antigens ; Cancer metastasis ; Clinical significance ; Hepatitis ; Hepatocellular carcinoma ; Immunohistochemistry ; Liver cancer ; Medical prognosis ; Medical research ; Metastasis ; Mortality ; Multivariate analysis ; Patients ; Statistical analysis ; Surgery ; Survival analysis</subject><ispartof>Oncology letters, 2020-11, Vol.20 (5), p.1-1</ispartof><rights>COPYRIGHT 2020 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2020</rights><rights>Copyright: © Wu et al. 2020</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c490t-7163234461fb3adb11e621a837c9f14a9329fea23805da523758ab61ca7d77a13</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471742/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471742/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27922,27923,53789,53791</link.rule.ids></links><search><creatorcontrib>Wu, Jingdong</creatorcontrib><creatorcontrib>Yang, Yongfei</creatorcontrib><creatorcontrib>Song, Jiansheng</creatorcontrib><title>Expression of SLC17A9 in hepatocellular carcinoma and its clinical significance</title><title>Oncology letters</title><description>The present study aimed to investigate the expression and clinical significance of solute carrier family 17 member 9 (SLC17A9) in cancer tissues of patients with hepatocellular carcinoma (HCC). Ninety-eight patients with HCC were admitted to our hospital from January 2010 to December 2014. Their clinical data was retrospectively analyzed. The expression of SLC17A9 in HCC cancer tissues was detected by immunohistochemistry. Kaplan-Meier curve, log-rank test and Cox proportional hazard model analysis were used to analyze the tumor-free survival rate and overall survival rate. SLC17A9 expression was associated with Edmondson grade (P=0.04) and distant metastasis (P=0.03). The tumor-free survival (P=0.03) and overall survival (P=0.01) of SLC17A9-high expression patients were significantly lower than those in SLC17A9-low expression patients. Multivariate analysis revealed that SLC17A9 expression (HR, 0.77; 95% CI, 0.27-2.47, P=0.02) was an independent risk factor for tumor-free survival in patients with HCC, and the expression of SLC17A9 (HR, 1.81; 95% CI, 0.99-3.77, P=0.04) was an independent risk factor for overall survival in patients with HCC. In conclusion, SLC17A9 can be used as a new molecular marker to predict the poor prognosis of patients with HCC. Key words: hepatocellular carcinoma, prognosis, molecular marker, SLC17A9, immunohistochemistry</description><subject>Adenosine triphosphate</subject><subject>Antigens</subject><subject>Cancer metastasis</subject><subject>Clinical significance</subject><subject>Hepatitis</subject><subject>Hepatocellular carcinoma</subject><subject>Immunohistochemistry</subject><subject>Liver cancer</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Metastasis</subject><subject>Mortality</subject><subject>Multivariate analysis</subject><subject>Patients</subject><subject>Statistical analysis</subject><subject>Surgery</subject><subject>Survival analysis</subject><issn>1792-1074</issn><issn>1792-1082</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptkk2LFDEQhoMo7jLu0XtAEC895qs7nYswDOsqDOxBPYeadDKTJZ2MSbfovze9u6yOmByqSJ56K1UphF5Tsua9Yu9TWDPCyJoyIvgzdEmlYg0lPXv-5Etxga5KuSN1tR3t--4luuBMcSGFukS31z9P2ZbiU8TJ4S-7LZUbhX3ER3uCKRkbwhwgYwPZ-JhGwBAH7KeCTfDRGwi4-EP0rrrR2FfohYNQ7NWjXaFvH6-_bj81u9ubz9vNrjFCkamRtOOMC9FRt-cw7Cm1HaPQc2mUowJUfaGzwHhP2gFaxmXbw76jBuQgJVC-Qh8edE_zfrSDsXHKEPQp-xHyL53A6_Ob6I_6kH5oKSSVglWBd48COX2fbZn06MtSLUSb5qKZELyt7apmhd78g96lOcda3kLJnrBWyD_UAYLVPrpU85pFVG86XvvOZKcqtf4PVfdgR29StM7X87OAt38FHC2E6VhSmKf6Y-UcbB5Ak1Mp2bqnZlCil2nRKehlWvT9tPDfXlqtLA</recordid><startdate>20201101</startdate><enddate>20201101</enddate><creator>Wu, Jingdong</creator><creator>Yang, Yongfei</creator><creator>Song, Jiansheng</creator><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20201101</creationdate><title>Expression of SLC17A9 in hepatocellular carcinoma and its clinical significance</title><author>Wu, Jingdong ; Yang, Yongfei ; Song, Jiansheng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c490t-7163234461fb3adb11e621a837c9f14a9329fea23805da523758ab61ca7d77a13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adenosine triphosphate</topic><topic>Antigens</topic><topic>Cancer metastasis</topic><topic>Clinical significance</topic><topic>Hepatitis</topic><topic>Hepatocellular carcinoma</topic><topic>Immunohistochemistry</topic><topic>Liver cancer</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Metastasis</topic><topic>Mortality</topic><topic>Multivariate analysis</topic><topic>Patients</topic><topic>Statistical analysis</topic><topic>Surgery</topic><topic>Survival analysis</topic><toplevel>online_resources</toplevel><creatorcontrib>Wu, Jingdong</creatorcontrib><creatorcontrib>Yang, Yongfei</creatorcontrib><creatorcontrib>Song, Jiansheng</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Jingdong</au><au>Yang, Yongfei</au><au>Song, Jiansheng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expression of SLC17A9 in hepatocellular carcinoma and its clinical significance</atitle><jtitle>Oncology letters</jtitle><date>2020-11-01</date><risdate>2020</risdate><volume>20</volume><issue>5</issue><spage>1</spage><epage>1</epage><pages>1-1</pages><issn>1792-1074</issn><eissn>1792-1082</eissn><abstract>The present study aimed to investigate the expression and clinical significance of solute carrier family 17 member 9 (SLC17A9) in cancer tissues of patients with hepatocellular carcinoma (HCC). Ninety-eight patients with HCC were admitted to our hospital from January 2010 to December 2014. Their clinical data was retrospectively analyzed. The expression of SLC17A9 in HCC cancer tissues was detected by immunohistochemistry. Kaplan-Meier curve, log-rank test and Cox proportional hazard model analysis were used to analyze the tumor-free survival rate and overall survival rate. SLC17A9 expression was associated with Edmondson grade (P=0.04) and distant metastasis (P=0.03). The tumor-free survival (P=0.03) and overall survival (P=0.01) of SLC17A9-high expression patients were significantly lower than those in SLC17A9-low expression patients. Multivariate analysis revealed that SLC17A9 expression (HR, 0.77; 95% CI, 0.27-2.47, P=0.02) was an independent risk factor for tumor-free survival in patients with HCC, and the expression of SLC17A9 (HR, 1.81; 95% CI, 0.99-3.77, P=0.04) was an independent risk factor for overall survival in patients with HCC. In conclusion, SLC17A9 can be used as a new molecular marker to predict the poor prognosis of patients with HCC. Key words: hepatocellular carcinoma, prognosis, molecular marker, SLC17A9, immunohistochemistry</abstract><cop>Athens</cop><pub>Spandidos Publications</pub><pmid>32934749</pmid><doi>10.3892/ol.2020.12043</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1792-1074 |
| ispartof | Oncology letters, 2020-11, Vol.20 (5), p.1-1 |
| issn | 1792-1074 1792-1082 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7471742 |
| source | Spandidos Publications Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Adenosine triphosphate Antigens Cancer metastasis Clinical significance Hepatitis Hepatocellular carcinoma Immunohistochemistry Liver cancer Medical prognosis Medical research Metastasis Mortality Multivariate analysis Patients Statistical analysis Surgery Survival analysis |
| title | Expression of SLC17A9 in hepatocellular carcinoma and its clinical significance |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T15%3A10%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expression%20of%20SLC17A9%20in%20hepatocellular%20carcinoma%20and%20its%20clinical%20significance&rft.jtitle=Oncology%20letters&rft.au=Wu,%20Jingdong&rft.date=2020-11-01&rft.volume=20&rft.issue=5&rft.spage=1&rft.epage=1&rft.pages=1-1&rft.issn=1792-1074&rft.eissn=1792-1082&rft_id=info:doi/10.3892/ol.2020.12043&rft_dat=%3Cgale_pubme%3EA638862769%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2447802547&rft_id=info:pmid/32934749&rft_galeid=A638862769&rfr_iscdi=true |